Inhibitory Effect of Antineoplaston A10 and AS2-1 on Human Hepatocellular Carcinoma.
-
- TSUDA HIDEAKI
- Departments of Anesthesiology, Kurume University School of Medicine
-
- IEMURA AKIHIRO
- Departments of Pathology, Kurume University School of Medicine
-
- SATA MICHIO
- Departments of Medicine, Kurume University School of Medicine
-
- UCHIDA MASAFUMI
- Departments of Radiology, Kurume University School of Medicine
-
- YAMANA KAZUNARI
- Departments of Surgery, Kurume University School of Medicine
-
- HARA HIROSHI
- Departments of Surgery, Kurume University School of Medicine
この論文をさがす
抄録
Antineoplastons, first described by Burzynski, are naturally occurring peptides and aminoacid derivatives which control neoplastic growth. Antineoplaston A10 (3-phenylacetylamino-2, 6-piperidinedione) is the first chemically identified antineoplaston and when it is administered orally it is hydrolysed in pancreatic juice to phenylacetylglutamine and phenylacetylisoglutamine in the ratio of 4 to 1. These metabolites are water soluble and have antitumor effect, they are further degraded to phenylacetic acid. The mixture of phenylacetylglutamine and phenylacetylisoglutamine in the ratio of 4 to 1 was formulated as Antineoplaston A10 injectable formulation. The mixture of phenylacetylglutamine and phenylacetic acid in the ratio of 1 to 4 was also shown to have antitumor effect in tissue culture study, then formulated as Antineoplaston AS2-1. The reported cytostatic inhibitory effect of A10 on human hepatocellular carcinoma cells and differentiation inducing effect of AS2-1 on various tumor cells suggest potential benefit for the treatment of human hepatocellular carcinoma since this tumor recurs frequently despite initial successful treatment. We report here the effects of Antineoplaston A10 and AS2-1 on cell proliferation, cell morphology, cell cycle, and DNA in human hepatocellular carcinoma cell lines. Both agents inhibited cell proliferation and increased the number of cells in G0 and G1 phases and Antineoplaston AS2-1 induced apoptosis, we also describe our clinical experience of a hepatocellular carcinoma (HCC) patient whose tumor, after incomplete transcatheter arterial embolization (TAE) for a 7 cm*7 cm HCC, has been stable for more than 15 months during which time he has been taking Antineoplaston AS2-1 continuously without any serious adverse effects.
収録刊行物
-
- Ｔｈｅ Ｋｕｒｕｍｅ Ｍｅｄｉｃａｌ Ｊｏｕｒｎａｌ
-
Ｔｈｅ Ｋｕｒｕｍｅ Ｍｅｄｉｃａｌ Ｊｏｕｒｎａｌ 43 (2), 137-147, 1996
久留米大学医学部 The Kurume Medical Journal 編集部